# US 2001/0018440 A1 · L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0018440 A1
- Document ID: US20010018440A1
- Status: Published application
- Kind: A1
- Application number: 09/765,928
- Filed: 2001-01-19
- Published: 2001-08-30
- Earliest claimed: 1996-11-15
- Assignees: Yale University and The University of Georgia Research Foundation, Inc.
- Inventors: Chung K. Chu; Yung-Chi Cheng; Fucheng Qu
- Web page: https://patentgrep.com/patent/US20010018440A1

## CPC

- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the discovery that certain P-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.

## Claims

### Claim 1

A method for treating a viral infection in a patient caused by Epstein-Barr virus, Varicella-Zoster virus or Kaposi's Sarcoma virus comprising administering to said patient a therapeutically effective amount of a compound according to the structure: 6
where R is H, F, Cl, Br, I, CH3 or CF3; and
R1 is H, a C1 to C20 acyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group.

### Claim 2 (depends on 1)

The method according to claim 1 where R is H, Br or I.

### Claim 3 (depends on 1)

The method according to claim 1 where R is Br or I.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said viral infection is caused by Epstein Barr virus and R is I.

### Claim 5 (depends on 1)

The method according to claim 1 where R1 is a C1 to C3 acyl group.

### Claim 6 (depends on 1)

The method according to claim 1 wherein said viral infection is caused by Varicella-Zoster virus and R is Br.

### Claim 7

A method for treating an Epstein-Barr virus infection in a patient comprising administering to said patient a therapeutically effective amount of a compound according to the structure: 7
where R is Br or I and R1 is H.

### Claim 8 (depends on 7)

The method according to claim 7 where R is I.

### Claim 9

A method for treating a Varicella-Zoster virus infection in a patient comprising administering to said patient a therapeutically effective amount of a compound according to the structure: 8
where R is Br or I and R1 is H.

### Claim 10 (depends on 9)

The method according to claim 9 where R is Br.

### Claim 11

A method for preventing or delaying the onset of EBV-related lymphoma or cancer or Kaposi's Sarcoma in patients comprising administering to a patient at risk for an EBV-related lymphoma or cancer or Kaposi's Sarcoma a therapeutically effective amount of a compound according to the formula: 9
where R is H, F, Cl, Br, I, CH3 or CF3; and
R1 is H, a C1 to C20 acyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group.

### Claim 12 (depends on 11)

The method according to claim 11 wherein said patient is imimunodeficient.

### Claim 13 (depends on 11)

The method according to claim 11 wherein said patient is an organ transplant patient.

### Claim 14 (depends on 11)

The method according to claim 11 wherein said patient has had a blood transfusion.

### Claim 15 (depends on 11)

The method according to claim 11 wherein R is I or Br.
